(Q42200351)

English

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation

scientific article published on June 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation (English)

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

refractory anemia

1 reference

based on heuristic

inferred from title

Refractory anemia with ring sideroblasts

1 reference

based on heuristic

inferred from title

author name string

Hadrian Szpurka

1

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Ramon Tiu

2

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Gurunathan Murugesan

3

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Samer Aboudola

4

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Eric D Hsi

5

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Karl S Theil

6

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Mikkael A Sekeres

7

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Jaroslaw P Maciejewski

8

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

language of work or name

0 references

publication date

1 June 2006

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

108

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

7

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

2173-2181

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Focus on myeloproliferative diseases and myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Signaling through the JAK/STAT pathway, recent advances and future challenges

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

The Jak-STAT pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Functional interactions between Stat5 and the glucocorticoid receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

29 May 2018

Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

29 May 2018

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

29 May 2018

The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

17 August 2018

JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

17 August 2018

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

17 August 2018

STAT3 is constitutively active in some patients with Polycythemia rubra vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

17 August 2018

Sideroblastic anaemia with reactive thrombocytosis versus myelodysplastic/myeloproliferative disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/16741247

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16741247

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16741247

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16741247

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16741247

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals

1 reference

https://pubmed.ncbi.nlm.nih.gov/16741247

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16741247

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2006-02-005751

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42200351&oldid=1935756251"